Chemotherapy regimens
| Chemotherapy regimen . | First-line treatment . | |||||
|---|---|---|---|---|---|---|
| Rituximab + chemotherapy (n = 407) . | Chemotherapy alone (n = 231) . | Overall (n = 638) . | ||||
| n . | % . | n . | % . | n . | % . | |
| CHOP | 208 | 51.1 | 78 | 33.8 | 286 | 44.8 |
| CNOP | 18 | 4.4 | 16 | 6.9 | 34 | 5.3 |
| CVP | 51 | 12.5 | 44 | 19.0 | 95 | 14.9 |
| Other* | 130 | 31.9 | 93 | 40.3 | 223 | 35.0 |
| Chemotherapy regimen . | First-line treatment . | |||||
|---|---|---|---|---|---|---|
| Rituximab + chemotherapy (n = 407) . | Chemotherapy alone (n = 231) . | Overall (n = 638) . | ||||
| n . | % . | n . | % . | n . | % . | |
| CHOP | 208 | 51.1 | 78 | 33.8 | 286 | 44.8 |
| CNOP | 18 | 4.4 | 16 | 6.9 | 34 | 5.3 |
| CVP | 51 | 12.5 | 44 | 19.0 | 95 | 14.9 |
| Other* | 130 | 31.9 | 93 | 40.3 | 223 | 35.0 |
This group includes 70 patients (46 of 130 [35%] rituximab plus chemotherapy and 24 of 93 [26%] chemotherapy alone) who received cyclophosphamide alone or as part of a regimen other than CHOP, CNOP, or CVP. It also includes 35 patients (23 of 130 [18%] rituximab plus chemotherapy and 12 of 93 [13%] chemotherapy alone) who received either fludarabine or cytarabine without cyclophosphamide.